Finanzas de Cogent Biosciences Inc (COGT)COGTCogent Biosciences Inc

Evaluating the bottom line, Cogent Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -129.17%, provide a clear picture of how effectively COGT converts its operational activities into shareholder value.

In the context of the broader market, COGT competes directly with industry leaders such as CGON and TLX. With a market capitalization of $5.43B, it holds a significant position in the sector. When comparing efficiency, COGT's gross margin of N/A stands against CGON's -239.24% and TLX's N/A. Such benchmarking helps identify whether Cogent Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Cogent has reported a consistent trend of negative net income, with Q2 2026 showing a net loss of $88.93 million. The current ratio is strong at 13.57, indicating good short-term financial health despite ongoing losses.